FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4239501771> ?p ?o ?g. }

• W4239501771 abstract "Abstract Background We studied the efficacy and safety of a second dose of lasmiditan for acute treatment of migraine. Methods SAMURAI and SPARTAN were double-blind, placebo-controlled Phase 3 studies in which individuals with migraine were randomized to oral lasmiditan 50mg (SPARTAN only), 100mg, 200mg, or placebo. Study drug was to be taken within 4 hours (h) of onset of a migraine attack (moderate or severe pain). A second dose of study drug was provided for rescue (patient not pain-free at 2h and took a second dose 2-24h post-first dose) or recurrence (patient pain-free at 2h, but experienced recurrence of mild, moderate, or severe migraine pain and took a second dose 2-24h after first dose). Randomization to second dose occurred at baseline; patients originally assigned lasmiditan were randomized to the same lasmiditan dose or placebo (2:1 ratio), and those originally assigned placebo received placebo. Data from SAMURAI and SPARTAN were pooled for efficacy and safety assessment of a second dose of lasmiditan. Results The proportion of patients taking a second dose was lower with lasmiditan versus placebo, and decreased with increasing lasmiditan dose; the majority who took a second dose did so for rescue. In patients taking lasmiditan as first dose, outcomes (pain free, most bothersome symptom [MBS] free) at 2h after a second dose for rescue were similar whether the second dose was lasmiditan or placebo (p>0.05 in all cases). In patients taking lasmiditan for first dose, outcomes at 2h after a second dose for recurrence were as follows: lasmiditan pooled versus placebo - pain free, 50% vs 32% (p>0.05); MBS free, 71% vs 41% (p=0.02); pain relief, 77% vs 52% (p=0.03). In patients whose first dose was lasmiditan, the incidence of treatment emergent adverse events (TEAEs) reported after the second dose was similar whether second dose was lasmiditan or placebo. Conclusions A second dose of lasmiditan showed some evidence of efficacy when taken for headache recurrence. There was no clear benefit of a second dose of lasmiditan for rescue treatment. The incidences of TEAEs were similar whether the second dose was lasmiditan or placebo." @default.
• W4239501771 created "2022-05-12" @default.
• W4239501771 creator A5002003404 @default.
• W4239501771 creator A5030018731 @default.
• W4239501771 creator A5063514584 @default.
• W4239501771 creator A5063618224 @default.
• W4239501771 creator A5071267554 @default.
• W4239501771 creator A5079819010 @default.
• W4239501771 creator A5084460133 @default.
• W4239501771 date "2019-06-03" @default.
• W4239501771 modified "2023-10-14" @default.
• W4239501771 title "Effect of a rescue or recurrence dose of lasmiditan on efficacy and safety in the acute treatment of migraine: Findings from the Phase 3 trials (SAMURAI and SPARTAN)" @default.
• W4239501771 doi "https://doi.org/10.21203/rs.2.10046/v1" @default.
• W4239501771 hasPublicationYear "2019" @default.
• W4239501771 type Work @default.
• W4239501771 citedByCount "0" @default.
• W4239501771 crossrefType "posted-content" @default.
• W4239501771 hasAuthorship W4239501771A5002003404 @default.
• W4239501771 hasAuthorship W4239501771A5030018731 @default.
• W4239501771 hasAuthorship W4239501771A5063514584 @default.
• W4239501771 hasAuthorship W4239501771A5063618224 @default.
• W4239501771 hasAuthorship W4239501771A5071267554 @default.
• W4239501771 hasAuthorship W4239501771A5079819010 @default.
• W4239501771 hasAuthorship W4239501771A5084460133 @default.
• W4239501771 hasBestOaLocation W42395017711 @default.
• W4239501771 hasConcept C126322002 @default.
• W4239501771 hasConcept C141071460 @default.
• W4239501771 hasConcept C142724271 @default.
• W4239501771 hasConcept C168563851 @default.
• W4239501771 hasConcept C197934379 @default.
• W4239501771 hasConcept C204243189 @default.
• W4239501771 hasConcept C204787440 @default.
• W4239501771 hasConcept C27081682 @default.
• W4239501771 hasConcept C2778541695 @default.
• W4239501771 hasConcept C3017583242 @default.
• W4239501771 hasConcept C42219234 @default.
• W4239501771 hasConcept C71924100 @default.
• W4239501771 hasConceptScore W4239501771C126322002 @default.
• W4239501771 hasConceptScore W4239501771C141071460 @default.
• W4239501771 hasConceptScore W4239501771C142724271 @default.
• W4239501771 hasConceptScore W4239501771C168563851 @default.
• W4239501771 hasConceptScore W4239501771C197934379 @default.
• W4239501771 hasConceptScore W4239501771C204243189 @default.
• W4239501771 hasConceptScore W4239501771C204787440 @default.
• W4239501771 hasConceptScore W4239501771C27081682 @default.
• W4239501771 hasConceptScore W4239501771C2778541695 @default.
• W4239501771 hasConceptScore W4239501771C3017583242 @default.
• W4239501771 hasConceptScore W4239501771C42219234 @default.
• W4239501771 hasConceptScore W4239501771C71924100 @default.
• W4239501771 hasLocation W42395017711 @default.
• W4239501771 hasLocation W42395017712 @default.
• W4239501771 hasLocation W42395017713 @default.
• W4239501771 hasOpenAccess W4239501771 @default.
• W4239501771 hasPrimaryLocation W42395017711 @default.
• W4239501771 hasRelatedWork W1990151540 @default.
• W4239501771 hasRelatedWork W2057844879 @default.
• W4239501771 hasRelatedWork W2167297145 @default.
• W4239501771 hasRelatedWork W2473050951 @default.
• W4239501771 hasRelatedWork W2805181790 @default.
• W4239501771 hasRelatedWork W2912030862 @default.
• W4239501771 hasRelatedWork W3007053288 @default.
• W4239501771 hasRelatedWork W3042223597 @default.
• W4239501771 hasRelatedWork W3162538154 @default.
• W4239501771 hasRelatedWork W3216898030 @default.
• W4239501771 isParatext "false" @default.
• W4239501771 isRetracted "false" @default.
• W4239501771 workType "article" @default.